De-risking Bispecifics Early-on: How tight is too tight? How weak is too weak?

Webinar Details

This webinar was recorded Wednesday, April 6th, 2022.

Speaker:  John Burke, PhD, Co-founder, President, & CEO of Applied BioMath

Duration: 1 hour

Abstract: Biologics are exciting therapeutics due to their specificity and developability, but single target antibodies may have on-target off-tissue binding which may impact safety or may not fully enable a therapeutic concept (e.g., cell engagers). Bispecific antibodies (bsAbs) may help with specificity and therapeutic concept, but development complexity, cost, and time are increased. It is common to not know how to predict bsAb properties early enough to enable decisions. 

This webinar will introduce two bsAb case studies, an antibody-ligand fusion and a T-Cell engager, where a web enabled model-informed drug discovery and development (MID3) analysis helped to generate actionable hypotheses early in a project to impact critical thinking and portfolio decisions. This analysis is useful for any scientist engaged in biotherapeutic development. 


Download the Webinar